Analysis of the shorter drug survival times for Janus kinase inhibitors and interleukin-17 inhibitors compared with tumor necrosis factor inhibitors in a real-world cohort of axial spondyloarthritis patients - a retrospective analysis from the RHADAR network.
Adalimumab
Ankylosing spondylitis
Bechterew´s disease
Drug persistence
Ixekizumab
Kaplan-meier analysis
Secukinumab
Tofacitinib
Upadacitinib
Journal
Rheumatology international
ISSN: 1437-160X
Titre abrégé: Rheumatol Int
Pays: Germany
ID NLM: 8206885
Informations de publication
Date de publication:
13 Aug 2024
13 Aug 2024
Historique:
received:
31
03
2024
accepted:
26
07
2024
medline:
13
8
2024
pubmed:
13
8
2024
entrez:
13
8
2024
Statut:
aheadofprint
Résumé
In recent years Janus kinase inhibitors (JAKi) have joined tumor necrosis factor inhibitors (TNFi) and interleukin (IL)-17 inhibitors (IL-17i) as approved disease modifying anti-rheumatic drugs (DMARD) for moderate to severe forms of axial spondyloarthritis (axSpA). Drug survival in axSpA patients has not been well studied in a real-world outpatient scenario since the approval of JAKi. We aimed to analyze the three drug classes based on modes of actions (MoA) for their persistence rates among German axSpA outpatients. A retrospective analysis of the RHADAR database for axSpA patients with a new initiation of TNFi, IL-17i, or JAKi treatment between January 2015 and October 2023 was conducted. Analyses included Kaplan-Meier curves and adjusted Cox regressions for drug discontinuation. 1222 new biological DMARD (TNFi [n = 954], IL-17i [n = 190]) or JAKi (n = 78) treatments were reported. The median drug survival was 31 months for TNFi, 25 for IL-17i, and 18 for JAKi. The corresponding 2-year drug survival rate was 79.6%, 72.6%, and 62.8% for TNFi, IL-17i, and JAKi, respectively. The probability for discontinuation for JAKi was significantly higher compared with TNFi (HR 1.91 [95% CI 1.22-2.99]) as well as for IL-17i compared with TNFi (HR 1.43 [95% CI 1.02-2.01]), possibly related to more frequent use of TNFis as first-line therapy. IL-17i and JAKi discontinuation probabilities were similar. Primary non-response was the reason for drug discontinuation in most cases across all MoA. TNFi treatment might persist longer than JAKi and IL-17i in German axSpA outpatients, possibly related to more severe or refractory disease in patients with JAKi-treated or IL-17i-treated axSpA.
Identifiants
pubmed: 39136784
doi: 10.1007/s00296-024-05671-9
pii: 10.1007/s00296-024-05671-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Maksymowych WP, Lambert RGW, Caplan L, van den Bosch FE, Østergaard M (2022) Improving the design of RCTs in non-radiographic axial spondyloarthritis. Nat Rev Rheumatol 18(8):481–489. https://doi.org/10.1038/s41584-022-00789-1 Epub 2022 May 13. PMID: 35562426
doi: 10.1038/s41584-022-00789-1
pubmed: 35562426
Gniadecki R, Bang B, Bryld LE, Iversen L, Lasthein S, Skov L (2015) Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. Br J Dermatol 172(1):244–252. https://doi.org/10.1111/bjd.13343 Epub 2014 Nov 30. PMID: 25132294
doi: 10.1111/bjd.13343
pubmed: 25132294
Egeberg A, Rosenø NAL, Aagaard D, Lørup EH, Nielsen ML, Nymand L et al (2022) Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries. Semin Arthritis Rheum 53:151979 Epub 2022 Feb 9. PMID: 35183936
doi: 10.1016/j.semarthrit.2022.151979
pubmed: 35183936
Kleinert S, Bartz-Bazzanella P, von der Decken C, Knitza J, Witte T, Fekete SP et al (2021) A Real-World Rheumatology Registry and Research Consortium: the German RheumaDatenRhePort (RHADAR) Registry. J Med Internet Res 23(5):e28164. https://doi.org/10.2196/28164 PMID: 34014170; PMCID: PMC8176344
doi: 10.2196/28164
pubmed: 34014170
pmcid: 8176344
Baraliakos X, Kiltz U, Kononenko I, Ciurea A (2023) Treatment overview of axial spondyloarthritis in 2023. Best Pract Res Clin Rheumatol 37(3):101858. https://doi.org/10.1016/j.berh.2023.101858 . Epub 2023 Sep 5. PMID: 37673758
Danve A, Deodhar A (2022) Treatment of axial spondyloarthritis: an update. Nat Rev Rheumatol 18(4):205–216. https://doi.org/10.1038/s41584-022-00761-z Epub 2022 Mar 10. PMID: 35273385
doi: 10.1038/s41584-022-00761-z
pubmed: 35273385
Yu CL, Yang CH, Chi CC (2020) Drug Survival of Biologics in Treating Ankylosing Spondylitis: A Systematic Review and Meta-analysis of Real-World Evidence. BioDrugs 34(5):669–679. https://doi.org/10.1007/s40259-020-00442-x . PMID: 32946076
Dougados M, Lardy-Cléaud A, Desfleurs E, Claudepierre P, Goupille P, Ryussen-Witrand A et al (2024) Impact of the time of initiation and line of biologic therapy on the retention rate of secukinumab in axial spondyloarthritis (axSpA): data from the French multicentre retrospective FORSYA study. RMD Open 10(1):e003942. https://doi.org/10.1136/rmdopen-2023-003942 PMID: 38428974; PMCID: PMC10910420
doi: 10.1136/rmdopen-2023-003942
pubmed: 38428974
pmcid: 10910420
Glintborg B, Lindström U, Giuseppe DD, Provan SA, Gudbjornsson B, Hetland ML et al (2022) One-year treatment outcomes of Secukinumab Versus Tumor necrosis factor inhibitors in Spondyloarthritis: results from five nordic Biologic registries Including more than 10,000 treatment courses. Arthritis Care Res (Hoboken) 74(5):748–758. https://doi.org/10.1002/acr.24523 Epub 2022 Mar 8. PMID: 33253491
doi: 10.1002/acr.24523
pubmed: 33253491
García-Dorta A, León-Suarez P, Peña S, Hernández-Díaz M, Rodríguez-Lozano C, González-Dávila E et al (2022) Association of Gender, diagnosis, and obesity with Retention Rate of Secukinumab in Spondyloarthropathies: results form a Multicenter Real-World Study. Front Med (Lausanne) 8:815881. https://doi.org/10.3389/fmed.2021.815881 PMID: 35096907; PMCID: PMC8792854
doi: 10.3389/fmed.2021.815881
pubmed: 35096907
Hernández-Cruz B, Otero-Varela L, Freire-González M, Busquets-Pérez N, García González AJ, Moreno-Ramos M et al (2024) Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: real-world data from the BIOBADASER registry. https://doi.org/10.1136/ard-2023-225271 . Epub ahead of print. PMID: 38594056 Ann Rheum Dis ard-2023-225271
UCB (2023) https://www.ucb.com/stories-media/Press-Releases/article/UCB-Receives-New-European-Commission-Approvals-for-BIMZELXRVbimekizumab-for-the-Treatment-of-Psoriatic-Arthritis-and-Axial-Spondyloarthritis . Accessed June 23, 2024
Strunz PP, Englbrecht M, Risser LM, Witte T, Froehlich M, Schmalzing M et al (2024) Drug survival superiority of tumor necrosis factor inhibitors and interleukin-17 inhibitors over Janus kinase inhibitors and interleukin-12/23 inhibitors in German psoriatic arthritis outpatients: retrospective analysis of the RHADAR database. Front Immunol 15:1395968. https://doi.org/10.3389/fimmu.2024.1395968 PMID: 38846940; PMCID: PMC11153701
doi: 10.3389/fimmu.2024.1395968
pubmed: 38846940
pmcid: 11153701
Kiltz U, Braun J, DGRh, Becker A, Chenot DEGAM et al (2019) JF, Long version on the S3 guidelines for axial spondyloarthritis including Bechterew’s disease and early forms, Update 2019: Evidence-based guidelines of the German Society for Rheumatology (DGRh) and participating medical scientific specialist societies an. Z Rheumatol 78(Suppl 1):3–64. German. https://doi.org/10.1007/s00393-019-0670-3 . PMID: 31784900
Team R, Core R (2018) A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria
Team RStudio (2016) RStudio: Integrated Development for R. RStudio, Inc, Boston, MA
Letarouilly JG, Salmon JH, Flipo RM (2021) Factors affecting persistence with biologic treatments in patients with rheumatoid arthritis: a systematic literature review. Expert Opin Drug Saf 20(9):1087–1094 Epub 2021 May 14. PMID: 33926364
doi: 10.1080/14740338.2021.1924146
pubmed: 33926364
D’Amico ME, Silvagni E, Carrara G, Zanetti A, Govoni M, Scirè CA et al (2021) Role of comorbidities on therapeutic persistence of biological agents in rheumatoid arthritis: results from the RECord-linkage On Rheumatic Disease study on administrative healthcare databases. Scand J Rheumatol 50(5):333–342. doi: 10.1080/03009742.2020.1855365. Epub 2021 Mar 4. PMID: 33660559
de Vries MK, Wolbink GJ, Stapel SO, de Vrieze H, van Denderen JC, Dijkmans BA et al (2007) Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis 66(9):1252–1254. https://doi.org/10.1136/ard.2007.072397 Epub 2007 May 1. PMID: 17472991; PMCID: PMC1955152
doi: 10.1136/ard.2007.072397
pubmed: 17472991
pmcid: 1955152
Pérez-Guijo VC, Cravo AR, Castro Mdel C, Font P, Muñoz-Gomariz E, Collantes-Estevez E (2007) Increased efficacy of infliximab associated with methotrexate in ankylosing spondylitis. Joint Bone Spine 74(3):254-8. https://doi.org/10.1016/j.jbspin.2006.08.005 . Epub 2007 Mar 1. PMID: 17387031
Arends S, Lebbink HR, Spoorenberg A, Bungener LB, Roozendaal C, van der Veer E et al (2010) The formation of autoantibodies and antibodies to TNF-α blocking agents in relation to clinical response in patients with ankylosing spondylitis. Clin Exp Rheumatol 28(5):661–668 Epub 2010 Oct 22. PMID: 20822711
pubmed: 20822711
Albrecht K, Marschall U, Callhoff J (2021) Prescription of analgesics in patients with rheumatic diseases in Germany: A claims data analysis. Z Rheumatol 80(Suppl 2):68–75. doi: 10.1007/s00393-021-00971-y. Epub 2021 Apr 7. PMID: 33825975; PMCID: PMC8752520
Krüger K, von Hinüber U, Meier F, Tian H, Böhm K, Jugl SM et al (2018) Ankylosing spondylitis causes high burden to patients and the healthcare system: results from a German claims database analysis. Rheumatol Int 38(11):2121–2131. https://doi.org/10.1007/s00296-018-4124-z Epub 2018 Aug 9. PMID: 30094685
doi: 10.1007/s00296-018-4124-z
pubmed: 30094685
Haibel H, Redeker I, Zink A, Callhoff J, Marschall U et al (2019) Health care and disease burden in persons with axial spondyloarthritis in Germany. Z Rheumatol 78(9):865–874. German. https://doi.org/10.1007/s00393-019-0650-7 . PMID: 31172266
Redeker I, Callhoff J, Hoffmann F, Marschall U, Haibel H, Sieper J et al (2020) The prevalence and impact of comorbidities on patients with axial spondyloarthritis: results from a nationwide population-based study. Arthritis Res Ther 22(1):210. https://doi.org/10.1186/s13075-020-02301-0 PMID: 32912264; PMCID: PMC7488243
doi: 10.1186/s13075-020-02301-0
pubmed: 32912264
pmcid: 7488243
Larid G, Baudens G, Tiemdjo-Djimaffo G, Coquerelle P, Goeb V, Guyot MH et al (2024) Retention rate of subcutaneous TNF inhibitors in axial spondyloarthritis in a multicentre study from the RIC-FRANCE network. Sci Rep 14(1):1374. https://doi.org/10.1038/s41598-024-52016-4 PMID: 38228719; PMCID: PMC10791989
doi: 10.1038/s41598-024-52016-4
pubmed: 38228719
pmcid: 10791989
Sumpton D, Kelly A, Craig JC, Hassett G, Kane B, Oliffe M et al (2022) Preferences for Biologic treatment in patients with psoriatic arthritis: a Discrete Choice Experiment. Arthritis Care Res (Hoboken) 74(8):1234–1243. https://doi.org/10.1002/acr.24782 Epub 2022 Jun 1. PMID: 34514744
doi: 10.1002/acr.24782
pubmed: 34514744
Aletaha D, Husni ME, Merola JF, Ranza R, Bertheussen H, Lippe R et al (2020) Treatment Mode preferences in Psoriatic Arthritis: a qualitative Multi-country Study. Patient Prefer Adherence 14:949–961 PMID: 32606613; PMCID: PMC7293411
doi: 10.2147/PPA.S242336
pubmed: 32606613
pmcid: 7293411
Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL et al (2022) Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med 386(4):316–326. https://doi.org/10.1056/NEJMoa2109927 . PMID: 35081280
EMA (2023) https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-9-12-january-2023 . Accessed 28 January 2024
Ngo MD, Zummer M, Andersen KM, Richard N (2022) First Biologic Drug Persistence in Patients With Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis: A Real-World Canadian Physicians’ Experience. J Clin Rheumatol 28(1):e210-e216. https://doi.org/10.1097/RHU.0000000000001693 . PMID: 33394832
Lopalco G, Venerito V, Cantarini L, Emmi G, Salaffi F, Di Carlo M et al (2019) Different drug survival of first line tumour necrosis factor inhibitors in radiographic and non-radiographic axial spondyloarthritis: a multicentre retrospective survey. Clin Exp Rheumatol 37(5):762–767 Epub 2019 Apr 16. PMID: 31025925
pubmed: 31025925
Michelena X, Zhao SS, Dubash S, Dean LE, Jones GT, Marzo-Ortega H (2021) Similar biologic drug response regardless of radiographic status in axial spondyloarthritis: data from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis registry. Rheumatology (Oxford) 60(12):5795–5800. https://doi.org/10.1093/rheumatology/keab070 PMID: 33502476; PMCID: PMC8645273
doi: 10.1093/rheumatology/keab070
pubmed: 33502476